Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01139437 · ClinicalTrials.gov registry record · Phase 1
Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01139437 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 45 participants.
The verdict
NCT01139437, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
Human parainfluenza virus type 2 (HPIV2) can result in severe respiratory illness in infants and young children. This study will test the safety of and immune response to an HPIV2 vaccine aimed at infants and children.
Interventions
- OTHER Placebo
- BIOLOGICAL Standard Dose HPIV2 Vaccine
- BIOLOGICAL Low dose HPIV2 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01139437
The ClinicalTrials.gov registry entry for NCT01139437 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01139437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01139437 about?
NCT01139437 is a clinical study titled "Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants". Human parainfluenza virus type 2 (HPIV2) can result in severe respiratory illness in infants and young children. This study will test the safety of and immune response to an HPIV2 vaccine aimed at infants and children.
What is the current status of trial NCT01139437?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2010-06. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01139437?
The interventions under investigation include: Placebo (OTHER), Standard Dose HPIV2 Vaccine (BIOLOGICAL), Low dose HPIV2 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01139437?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.